Total Payments
$25,425
2024 Payments
$3,689
Companies
45
Transactions
1,382
Medicare Patients
4,877
Medicare Billing
$2.2M
Payment Breakdown by Category
Food & Beverage$25,276 (99.4%)
Education$149.14 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $25,276 | 1,376 | 99.4% |
| Education | $149.14 | 6 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $5,238 | 242 | $0 (2024) |
| Relypsa, Inc. | $3,174 | 196 | $0 (2020) |
| OPKO Pharmaceuticals, LLC | $2,498 | 161 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $1,500 | 75 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $1,460 | 82 | $0 (2024) |
| Amgen Inc. | $1,449 | 67 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $1,292 | 76 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $1,239 | 62 | $0 (2024) |
| Travere Therapeutics, Inc. | $943.17 | 49 | $0 (2024) |
| Horizon Therapeutics plc | $936.56 | 53 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,689 | 169 | AstraZeneca Pharmaceuticals LP ($415.74) |
| 2023 | $3,430 | 179 | AstraZeneca Pharmaceuticals LP ($804.29) |
| 2022 | $2,799 | 150 | AstraZeneca Pharmaceuticals LP ($1,028) |
| 2021 | $2,820 | 141 | AstraZeneca Pharmaceuticals LP ($1,292) |
| 2020 | $3,109 | 157 | AstraZeneca Pharmaceuticals LP ($1,062) |
| 2019 | $3,542 | 204 | AstraZeneca Pharmaceuticals LP ($619.57) |
| 2018 | $2,701 | 168 | Relypsa, Inc. ($806.68) |
| 2017 | $3,336 | 214 | Relypsa, Inc. ($1,311) |
All Payment Transactions
1,382 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $23.36 | General |
| 12/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $29.59 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Diabetes | ||||||
| 12/16/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Phosphate binder for ESRD | ||||||
| 12/09/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $28.31 | General |
| Category: Inflammation | ||||||
| 12/03/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: NEPHROLOGY | ||||||
| 12/02/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $19.58 | General |
| 11/26/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $31.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/13/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $10.90 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $31.56 | General |
| 11/04/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $24.80 | General |
| 10/31/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: Diabetes | ||||||
| 10/30/2024 | AKEBIA THERAPEUTICS INC | Auryxia (Drug), Vafseo | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: Nephrology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/28/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/23/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $27.47 | General |
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: DIABETES | ||||||
| 10/22/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: NEPHROLOGY | ||||||
| 10/16/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Phosphate binder for ESRD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,290 | 3,812 | $1.1M | $522,722 |
| 2022 | 10 | 1,142 | 3,397 | $1.1M | $535,544 |
| 2021 | 12 | 1,224 | 3,753 | $1.2M | $590,111 |
| 2020 | 14 | 1,221 | 3,830 | $1.2M | $520,101 |
Total Patients
4,877
Total Services
14,792
Medicare Billing
$2.2M
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 87 | 670 | $416,740 | $200,232 | 48.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Facility | 2023 | 31 | 231 | $143,066 | $69,600 | 48.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 245 | 965 | $132,205 | $65,325 | 49.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 375 | 862 | $117,232 | $47,616 | 40.6% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 20 | 185 | $91,390 | $44,756 | 49.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 118 | 136 | $50,592 | $19,318 | 38.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 89 | 308 | $44,660 | $18,586 | 41.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 43 | 61 | $30,500 | $15,468 | 50.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 90 | 142 | $35,926 | $15,334 | 42.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 86 | 86 | $26,746 | $11,779 | 44.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Facility | 2023 | 15 | 23 | $11,500 | $5,651 | 49.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 67 | 90 | $12,240 | $4,830 | 39.5% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 13 | 42 | $6,342 | $3,105 | 49.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 11 | $2,167 | $1,121 | 51.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 81 | 712 | $442,864 | $221,812 | 50.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Facility | 2022 | 34 | 310 | $192,820 | $96,603 | 50.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 371 | 798 | $108,528 | $57,708 | 53.2% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 22 | 178 | $87,932 | $43,023 | 48.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 191 | 685 | $93,845 | $41,366 | 44.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 69 | 268 | $38,860 | $16,640 | 42.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 89 | 89 | $33,108 | $14,988 | 45.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 89 | 120 | $30,360 | $13,527 | 44.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 86 | 86 | $26,746 | $12,384 | 46.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 77 | 115 | $15,640 | $8,171 | 52.2% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 19 | 20 | $10,000 | $5,182 | 51.8% |
About Dr. Kevin Pham, M.D
Dr. Kevin Pham, M.D is a Nephrology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477623635.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Pham, M.D has received a total of $25,425 in payments from pharmaceutical and medical device companies, with $3,689 received in 2024. These payments were reported across 1,382 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($25,276).
As a Medicare-enrolled provider, Pham has provided services to 4,877 Medicare beneficiaries, totaling 14,792 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Orange, CA
- Active Since 11/08/2006
- Last Updated 08/18/2008
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1477623635
Products in Payments
- LOKELMA (Drug) $4,111
- Veltassa (Drug) $3,174
- ACTHAR (Biological) $1,738
- RAYALDEE (Drug) $1,291
- Rayaldee (Drug) $1,176
- Auryxia (Drug) $1,117
- FARXIGA (Drug) $1,089
- JYNARQUE (Drug) $1,044
- KRYSTEXXA (Biological) $886.90
- AURYXIA (Drug) $865.67
- Velphoro (Drug) $857.32
- Parsabiv (Drug) $638.51
- Parsabiv (Biological) $564.03
- BENLYSTA (Biological) $500.32
- TARPEYO (Drug) $455.74
- SAMSCA (Drug) $455.10
- JARDIANCE (Drug) $452.37
- NORTHERA (Drug) $448.87
- Not Product Related (Medical Supply) $322.61
- Kerendia (Drug) $319.65
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Orange
Dr. Yasir Qazi, M.d, M.D
Nephrology — Payments: $613,561
Nephrology $613,561
Dr. Kamyar Kalantar-Zadeh, M.d, M.D
Nephrology — Payments: $502,256
Nephrology $502,256
Dr. Ramy Hanna, M.d, M.D
Nephrology — Payments: $373,673
Nephrology $373,673
David Simon, Md, MD
Nephrology — Payments: $59,814
Nephrology $59,814
Dr. Rebecca Ahdoot, M.d, M.D
Nephrology — Payments: $54,072
Nephrology $54,072
Thu Le, M.d, M.D
Nephrology — Payments: $19,032
Nephrology $19,032